We’re excited to present our latest data on tumor-targeted antibody-drug conjugates (ADCs) at ESMO 2025 in Berlin. Join us to discover how our proprietary platform technologies are reshaping the future of targeted cancer therapies.

The Festival of Biologics brings together pharma & biotech, academics, research institutes, regulators, patients groups and payers together with their partners across the value chain to bring you from discovery to market.

Join us in Boston at the leading industry event focused on innovative linker and conjugation strategies for next-generation ADC development.

Philipp Ochtrop, Director of Chemistry at Tubulis, will give a talk on advancing ADC design through novel linker technologies. His presentation, “Unlocking Novel Payloads for Antibody-Drug Conjugates Through Targeted Delivery of Hydroxyl-Linked Drugs via Alco5” will highlight Tubulis’ approach to expanding the therapeutic potential of ADCs beyond current payload limitations.